Ex­elix­is posts mixed re­sults for Cabome­tyx com­bo in ear­ly liv­er can­cer pa­tients, cast­ing doubt on piv­otal read­out

Ex­elix­is en­vi­sioned a first-line ap­proval for its su­per-sell­er Cabome­tyx in liv­er can­cer, but af­ter an in­ter­im read­out pro­duced mixed re­sults, that pic­ture is now a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER